tirzepatide type 1 diabetes trial in Adults With Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical @DiabetesCareADA 🔻 −10.3 kg in 12 weeks with tirzepatide vs −0.7 kg with placebo (P<0.0001) 🎯 100% ≥5% Tirzepatide for diabetes: on track

It was demonstrated that GSH level affects the selective elimination of mitochondria (mitophagy) in S

February 21, 2026 By: Shelby Tadin Organic: Healthier or hype

The Risks of Compounded GLP-1 Drugs Many clinicians are happy to prescribe compounded GLP-1 weight loss drugs, but some experts caution that the limited oversight may expose patients to unnecessary risks

Tirzepatide is a groundbreaking injectable medication that targets both GLP-1 and GIP receptors, helping to regulate appetite, improve blood sugar levels, and promote sustainable weight loss

This assessment does not predict your exact medication response or side effect profile, but knowing your genetic predispositions can help you and your provider anticipate which tirzepatide strategies may align best with your individual physiology and optimize your injection schedule accordingly

Conclusion Due to the rise in GLP-1RA prescribing for weight loss, we recommend clinicians be vigilant regarding unremitting nausea/vomiting that occurs with lurasidone and possibly other second-generation antipsychotics upon initiation of GLP-1RAs